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Abstract
Systemic Lupus Erythematosus is a disease that manifests in many different ways . The cause of lupus still remains elusive . 
However, many of the pathologies associated with the disease as well as the disease process have been described . The patho-
physiology of the disease as well as its effects on specific patient groups will be discussed below. More specifically, Systemic Lupus’ 
effect on pregnancy with current diagnostic and treatment modalities will be the focus of this paper .
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Introduction
Systemic Lupus Erythematosus (SLE) is an autoimmune 
disease that is common and affects around 400 per 
100,000 people in certain populations.  SLE mainly affects 
African or Hispanic women, especially during their repro-
ductive years.  The telltale sign of SLE is the production of 
autoantibodies, specifically antinuclear antibodies (ANAs). 
The most common method for detecting these ANAs is 
indirect immunofluorescence, which can recognize anti-
bodies that bind to nuclear antigens, such as DNA, RNA, 
and proteins.  Besides ANAs, patients with SLE have a va-
riety of other autoantibodies that fight against red blood 
cells, platelets, and lymphocytes.  The causes of SLE, like 
most autoimmune diseases, are unknown.  However, ge-
netic, environmental, and immunological factors seem to 
play a role (Kumar, et. al. 2018).  Fatigue, joint pain, and rash 
are the most common symptoms of SLE.  SLE is unique 
because of the disease’s ability to appear and disappear 
called flares.  Flares are known to occur during rapid hor-
monal changes, as occurs in pregnancy.  For women with 
SLE, pregnancy is a major concern.  Pregnancy is a high-
risk time for SLE patients because flares during pregnancy 
may be related to increased irreversible organ damage 
(Ateka-Barrutia, Khamashta, 2013).  The risk of flare 
during pregnancy depends on the disease activity 6-12 
months before conception; the risk is higher in those 
who have had repeated flares preconception.  Therefore, 
women living with SLE who are thinking about conceiving 
should consult their rheumatologist prior to conceiving, 
so that they can monitor disease activity to ensure the 
best outcome for mother and baby. 
Methods
The data in this paper was compiled using Pubmed, 
ProQuest, and Google Scholar.  PubMed and Proquest 
were accessible through Touro College’s Online Library 
system. Key terms used to search were: “SLE pregnancy”, 
“SLE”, “hydroxychloroquine”, and “autoimmune diseases”.
Discussion 
Pathogenesis of Systemic Lupus Erythematosus
The principle deficiency in SLE is the failure of the mecha-
nisms that maintain self-tolerance.  Although the cause(s) 
of the lack of self-tolerance remains unknown, there are 
several genetic, environmental, and immunological factors 
that seem to play a role.  
There is a lot of evidence that suggests a genetic pre-
disposition to SLE.  Family members have a higher risk of 
developing SLE, and even twenty percent of uninfluenced 
first-degree family members have autoantibodies.  The 
concordance of SLE in monozygotic twins is twenty-five 
to fifty percent and around five percent in dizygotic twins, 
which suggests that genetic factors play a crucial role in 
the predisposition of SLE (Kumar, et. al. 2018).  The above 
said indicates a polygenic inheritance of the disease- it 
is approximated that at least 4 susceptibility genes are 
required in order to develop SLE (Schur, 1995). 
Studies reveal that SLE susceptibility involves human 
leucocyte antigen (HLA) class II gene polymorphisms.  In 
patients from different backgrounds, a relation between 
HLA DR2 and DR3 with SLE is a regular finding with an 
odds ratio for developing SLE of roughly 2 to 5 (Pisetsky, 
1997).  Which means, a person with HLA DR2 and DR3 are 
two to five times more likely to develop SLE than a person 
without HLA DR2 and DR3.  HLA class II genes have also 
been linked to the presence of some autoantibodies, for 
example: anti-Sm, anti-Ro, anti-La, anti-nRNP, and anti-DNA 
antibodies.  HLA class III genes, specifically those “encoding 
complement components C2 and C4”, are major contrib-
utors in the development of SLE.  Patients with homozy-
gous C4A null alleles, regardless of their background, have 
a higher risk of having SLE.  Additionally, SLE is connected 
to inherited deficiencies of C1q, C1r/s, and C2 (Mok, Lau, 
2003).  A reduction in complement activity could encour-
age SLE susceptibility by damaging the neutralization and 
removal of foreign and self-antigens.  “When the antigen 
burden overwhelms the clearance capacity of the immune 
system, autoimmunity may ensue” (Mok, Lau, 2003).  Other 
polymorphic genes have been linked to SLE such as: tumor 
necrosis factor alpha, interleukin six, the T cell receptor, 
CR1, Fc gamma RIIA and Fc gamma RIIIA, immunoglobu-
lin Gm and Km allotypes, and heat shock protein seventy 
(Sullivan, 2000).  Nonetheless, in majority of cases, consis-
tent results were not reported in studies of patients from 
different ethnic backgrounds. 
 Although genetic factors play a crucial role in regard to 
the predisposition towards SLE, the start of the disease 
stems from environmental triggers.  Infectious agents, 
such as bacterial DNA/endotoxins and retroviruses, may 
cause particular reactions by molecular imitation and dis-
rupt immunoregulation.  Viruses might set off or induce a 
flare in lupus by harming tissues to release autoantigens, 
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triggering B cells, and inducing SLE by molecular imita-
tion.  But, viral findings have not been consistent in the 
tissues of people with lupus (Herrmann, et. al. 1996). 
Therefore, there is not enough evidence to defend that 
any one infectious agent causes SLE.  Certain diet choic-
es, like alfalfa sprouts and high intake of saturated fats, 
influences the making of inflammatory mediators.  Alfalfa 
sprouts contain L-canavanine which has been associat-
ed with the development of SLE-like symptoms (Prete, 
1985).  Procainamide, hydralazine, chlorpromazine, iso-
niazid, phenytoin, and penicillamine are drugs that alter 
“cellular responsiveness and immunogenicity of self-an-
tigens” (Mok, Lau, 2003).  Procainamide and hydralazine 
are aromatic amines or hydrazines, and they can cause 
an SLE-like disorder (Adams, Mongey, 1994).  Ultraviolet 
light may aggravate SLE in many patients. UV light can 
trigger inflammation, promote cellular apoptosis, and in-
duce tissue damage.  Exposure to the sun’s light causes 
and aggravates SLE.  Exposure of skin to ultraviolet light 
changes the location and/or chemistry of DNA, Ro, and 
nRNP antigens, and also amplifies their immunogenicity. 
Recent studies have shown that ultraviolet light causes 
the apoptosis of human keratinocytes, which brings about 
the development of clusters on the exterior of dying cells, 
that hold nuclear and cytoplasmic antigens.  This supplies 
a method for the exposure of self-antigens to the im-
mune system and evokes autoimmunity (Mok, Lau, 2003). 
To summarize: UV light and other environmental fac-
tors cause the apoptosis of cells.  Insufficient removal of 
the nuclei of these cells leads to a large burden of nucle-
ar antigens.  Underlying abnormalities in B lymphocytes 
and T lymphocytes are accountable for flawed tolerance, 
and, as a result, self-reactive lymphocytes live on and stay 
functioning.  Said lymphocytes are activated by nuclear 
self-antigens, and antibodies are made to fight the an-
tigens. Complexes of the antigens and antibodies stick 
to Fc receptors on dendritic cells and B cells and might 
be engulfed.  The nucleic acid elements engage toll-like 
receptors (TLRs) and trigger B cells to create more au-
toantibodies.  TLR stimuli also trigger dendritic cells to 
make interferons and other cytokines, which intensifies 
the immune response and induces more apoptosis.  The 
overall result is a “cycle of antigen release and immune 
activation resulting in the production of high-affinity au-
toantibodies” (Kumar, et. al. 2018).
Autoantibodies
The number one hallmark, and the number one concern, 
of lupus is the production of autoantibodies.  These an-
tibodies attack the patient’s own molecules found in the 
cytoplasm, nucleus, cell surface, and soluble molecules like 
coagulation factors and IgG.  Antinuclear antibodies are 
found in more than ninety five percent of SLE patients; an-
ti-double stranded DNA (ds-DNA) and anti-Sm antibodies 
are specific for SLE and not found in patients with other 
autoimmune diseases, making them very important in the 
diagnosis (Tan, et. al. 1982).  ANAs can be divided into 4 
groups: antibodies to DNA, antibodies to nucleolar anti-
gens, antibodies to nonhistone proteins bound to RNA, 
and antibodies to histones.  Additionally, many other auto-
antibodies are found in patients with SLE.  These autoan-
tibodies attack lymphocytes, platelets, and red blood cells. 
Thirty to forty percent of SLE patients have anti-phospho-
lipid antibodies.  These patients have complications sec-
ondary to excessive clotting (Kumar, et. al. 2018). 
Symptoms of SLE
SLE is a chronic disease, meaning that the disease is long 
lasting, in this case specifically, the disease waxes and 
wanes.  The symptoms and the effects on daily life of SLE 
vary, however, there are some that were seen in near-
ly all patients.  A group of patients were selected from 
6 rheumatology practices that were spread across the 
United States between May and July 2014.  These patients 
were between the ages of eighteen and seventy-five and 
had a clinical diagnosis of lupus.  Ninety eight percent 
of patients reported they felt fatigue, ninety three per-
cent reported joint pain, eighty eight percent reported a 
rash, eighty percent reported swelling of feet, legs, fingers, 
or hands and joint stiffness.  Because SLE is chronic it 
has major effects on a patient’s daily life and activities. 
Sixty one percent of those interviewed had difficulty 
with housework, thirty nine percent had difficulty driving 
and sleeping, and twenty two percent had difficulty car-
ing for children.  Sixty two percent of the patients who 
participated in this study were not working outside the 
home; ninety one percent said that this was caused by 
SLE (Mathias, et. al. 2018).
Hormonal Effects on SLE
Lupus is primarily a female disease; it is “characterized by a 
9:1 female to male ratio of disease incidence” (Weckerle, 
Niewold, 2011).  Generally, SLE occurs between puberty 
and menopause, the reproductive age range (15:1 ratio). 
Occurrence of SLE before puberty and after menopause 
is uncommon.  Furthermore, patients with a hypergo-
nadotrophic disorder, namely Klinefelter’s Syndrome, are 
prone to lupus as well.  From these observations, it is as-
sumed that endogenous sex hormones play a major role 
in lupus (Mok, Lau, 2003).  
Epidemiological studies show a connection between 
the use of exogenous estrogens and the emergence of 
59
Lupus and the Effects on Pregnancy
lupus.  The Nurses’ Health Study revealed that hormonal 
replacement therapy and the use of oral contraceptive 
pills have an association with an increased chance of 
developing SLE (Sanchez-Guerrero, et. al. 1997).  Lupus 
improvement was observed in patients who had gone 
through menopause or an oophorectomy.  Conversely, 
lupus flares mainly occur during hormonal changes, such 
as pregnancy, exogenous estrogen administration, puerpe-
rium, and ovulation during IVF (Mok, Wong, 2001).  Many 
patients exhibit disease flares during the second half of 
their menstrual cycle, this has been attributed to the mid-
cycle estrogen surge.  Additionally, patients who develop 
lupus after the age of fifty were reported to have a milder 
disease and less significant organ involvement.  All these 
observations are helpful in explaining and understanding 
why pregnancy for SLE patients is extremely difficult. 
Pregnancy and SLE Pregnancy
Healthy, normal pregnancy causes the body to go through 
many physiological changes; these changes may influence 
rheumatic disease expression.  Most organ systems go 
through some level of change during pregnancy.  The glo-
merular filtration rate goes up by fifty percent during a 
normal pregnancy.  Subsequently, women with preceding 
proteinuria might be expected to have a noticeable rise in 
urinary protein excretion in the 2nd and 3rd trimesters. 
There is also an expected thirty-fifty percent elevation in 
intravascular volume; women who have cardiac or renal 
compromise might not endure this well. Additionally, 
blood counts are usually different during pregnancy. 
Anemia is usual due to hemodilution, and in eight percent 
of uncomplicated pregnancies there is an occurrence of 
thrombocytopenia.  The chance of venous thromboem-
bolism increases by fivefold during normal pregnancy, 
because of the prothrombotic state that pregnancy cre-
ates along with compression by the expecting uterus and 
venous stasis (Sammaritano, 2016). 
 In normal pregnancy, the mother’s immune system is 
altered in order to ensure fetal health and survival: im-
munoglobulin secretion rises, cell mediated immunity 
decreases, and pregnancy-specific proteins work to in-
hibit lymphocyte function (Branch, Wong, 2014). General 
immunosuppression would reduce maternal resistance 
against infection, so instead, there is an activation in 
the maternal immune system during pregnancy of im-
mune-modulatory molecules and immunocompetent 
cells (Ostensen, Clowse, 2013).  Cytokines and chemok-
ines manage these immunocompetent cells with T helper 
cells; cytokines are an important factor in supporting suc-
cessful pregnancy.  The Th1/Th2 cytokine shift is a crucial 
immunological change that occurs during pregnancy.  Th2 
includes numerous interleukins which trigger antibody 
synthesis and humoral immunity.  In pregnancy a preva-
lence of the Th2 response might be anticipated, and since 
lupus is predominantly a Th2-mediated disorder, aggrava-
tion of the disorder is more likely (de Jesus, et. al. 2015).  
Pregnancy is high-risk for women with SLE, because 
disease flares during pregnancy have been linked to 
organ damage.  Therefore, it is recommended that every 
woman with lupus should receive a preconception evalu-
ation which should assess organ damage related to lupus, 
medications, and disease activity.  If a patient is taking 
medications for lupus that have adverse effects on preg-
nancy, it is suitable for the patient to change to a lower 
risk medication (Flint, et. al. 2016).    Additionally, for the 
best pregnancy outcome and for the mother’s safety, it is 
advised that women with SLE should conceive during a 
time of inactive disease.  Disease flares during pregnancy 
have been linked to disease activity six to twelve months 
before conception.  Lupus flare within 6 months prior 
to conception has been linked to a significant rise in the 
chance of flare during pregnancy and a fourfold increase 
in pregnancy loss (Clowse, 2007). 
Pregnancy for women with lupus has been linked 
to: risk of flare, preeclampsia, hypothyroidism, stroke, 
preterm birth, hypertension, pre-gestational diabetes, 
caesarean section, placental deficiencies leading to intra-
uterine growth restriction (IUGR), pregnancy loss, and 
even death.  The Danish National Registry stated that ma-
ternal complications were found in fifty percent of lupus 
pregnancies (Jakobsen, et. al. 2015).  A recent study ob-
served thirteen thousand five hundred and fifty-five SLE 
pregnancy deliveries.  Twenty five percent of SLE pregnan-
cies were delivered preterm, meaning the pregnancy was 
shorter than thirty-seven weeks (Yan Yuen, et. al. 2008). 
Six to thirty five percent of babies were born small for 
gestational age.  One in five lupus pregnancies ended in 
pregnancy loss (compared with one in ten from controls), 
with a four to six-fold increased likelihood of stillbirths 
compared with controls (Clark, et. al. 2003).  Disease 
activity within six months before conception has been 
linked to an increased rate of fetal loss.  Patients with 
anti-dsDNA antibodies have the highest risk for preterm 
birth and pregnancy loss.  Patients with lupus have a three 
to four-fold increased chance of developing preeclamp-
sia.  Antiphospholipid antibodies are found in thirty-forty 
percent of SLE patients and have been linked to negative 
obstetric outcomes.  Women with aPL antibodies have 
an increased chance of developing IUGR, preeclampsia, 
preterm birth, and fetal loss (Smyth, et. al. 2010).  
The PROMISSE study observed three hundred and eighty 
five women with lupus and found that fifteen percent of 
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them experienced a mild flare, whereas five percent ex-
perienced an extreme flare.  Sixty percent of women with 
active SLE prior to conception experienced flares during 
pregnancy, however, only ten percent of women with in-
active SLE prior to conception experienced flares during 
pregnancy (Buyon, et. al. 2015).   A study conducted in 
Sweden observed five hundred and fifty one first singleton 
births to patients with lupus and assessed their outcomes 
in comparison to the general population.  This study includ-
ed twelve thousand eight hundred and forty seven nor-
mal pregnancies, one hundred and ninety eight pre-lupus 
women, sixty five women who were first diagnosed with 
lupus zero-two years after giving birth, and one hundred 
and thirty three women who were diagnosed two-five 
years postpartum.  Compared to those who were diag-
nosed with lupus two-five years after their first pregnancy, 
those with lupus during their first pregnancy, or diagnosed 
soon after, had the highest risk of poor clinical outcomes. 
Twenty six percent of women who were diagnosed with 
lupus zero-two years after giving birth had preeclampsia 
during pregnancy, thirteen percent of women who were 
diagnosed two-five years after giving birth had preeclamp-
sia during pregnancy, and sixteen percent of women who 
had lupus while pregnant had preeclampsia; while only 
approximately five percent of women without lupus had 
preeclampsia (Arkema, et. al. 2016).  
Over the last forty years some of the adverse preg-
nancy outcomes have improved.  A study compared lupus 
pregnancies from forty years earlier to their current preg-
nancy group, which consisted of eighty three pregnant 
women.  The rate of pregnancy loss decreased dramati-
cally from forty percent to seventeen percent, compared 
with the general population rate of sixteen percent.  On 
the other hand, the preterm delivery rate did not change 
dramatically. It only dropped from thirty seven percent to 
thirty two percent versus nine to twelve percent preterm 
delivery rate of the general population (Clark, et. al. 2005). 
A Norwegian study analyzed pregnant women with con-
nective tissue diseases, including lupus, over the last four 
decades. Although maternal and fetal complications were 
more prevalent in lupus patients compared to the gener-
al population, the number of births did increase and the 
rate of C-sections, low birth weight infants, and preterm 
births decreased (Wallenius, et. al. 2015).  
Effects of SLE on the Baby
Complications during pregnancy can impact fetal and neo-
natal outcomes.  There is an increased chance of preterm 
delivery, preeclampsia, fetal loss, and low birth weight ba-
bies in women with lupus.  When maternal autoantibodies, 
aPL antibodies, anti-Ro/SS-A and anti-La/SS-B antibodies 
are present there are more precise risks.  The presence of 
aPL antibodies has been commonly linked to prematurity 
and intrauterine growth restriction.          Anti-Ro or an-
ti-La antibodies are found in around thirty percent of SLE 
patients.  These autoantibodies can cross the placenta by 
active transport between the sixteenth and thirtieth weeks 
of pregnancy.  Babies who are born to women with anti-Ro/
SS-A and anti-La/SS-B antibodies have an increased risk of 
having neonatal lupus erythematosus (Sammaritano, 2016). 
These autoantibodies have been linked to the development 
of congenital complete heart block and noncardiac neona-
tal lupus erythematosus expressions such as: transamini-
tis, reversible thrombocytopenia, and photosensitive rash 
(Brito-Zero’n, et. al. 2014).  
Congenital complete heart block is the most seri-
ous condition linked to anti-Ro/SS-A and anti-La/SS-B 
antibodies and occurs in approximately two percent of 
babies born to mothers with these antibodies.  If the 
mother previously had a child with congenital heart block, 
then the risk for the second child having it increases to 
eighteen percent; if the mother previously had two chil-
dren with congenital heart block then the risk increases 
to fifty percent (Brucato, et. al. 2001).  In more than eighty 
percent of children with congenital heart block the moth-
er had anti-Ro or anti-La antibodies.  Typically, congenital 
heart block develops between sixteen and twenty four 
weeks of pregnancy, and it can be recognized by low fetal 
heart rate which is less than sixty beats per minute.  Anti-
Ro and anti-La antibodies attack the myocardium and 
fetal atrioventricular node.  This causes immune mediated 
inflammation and fibrosis in tissues that are affected, re-
sulting in various levels of heart block or cardiomyopathy 
(Llanos, et. al. 2012).  The risk of death for babies affected 
is around ten-twenty percent and most of those who sur-
vive require a permanent pacemaker.  
Various treatments for congenital heart block have 
been tried.  Because of their capability to diffuse across 
the placenta, fluorinated steroids are used for cases that 
involve myocarditis, hydrops, or incomplete heart block 
due to its potential to reverse the affects (Friedman, et. 
al. 2009).  Exposure to hydroxychloroquine throughout 
pregnancy might lower the chances of development of 
congenital heart block (Izmirly, et. al. 2012). 
Treatments/Management of SLE Pregnancy
Firstly, patients with lupus who are considering pregnancy 
should be closely followed by their rheumatologist and 
obstetrician.  Lupus should be quiescent, and the patient 
should be on medications that are low risk for approx-
imately 6 months before conception.  Recent studies 
show that antimalarial medications are beneficial for the 
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mother and baby and have few side effects, and there-
fore should be taken throughout pregnancy.  In one study 
of one hundred and eighteen lupus pregnancies, poor 
pregnancy outcomes were dramatically reduced in the 
women who were taking hydroxychloroquine.  “Preterm 
delivery rates were 15.8% in that group versus 44.2% in 
untreated patients, and rates of IUGR were 10.5% ver-
sus 28.6%” (Leroux, et. al. 2015).  In a different study, 
women who stopped taking hydroxychloroquine suffered 
remarkably more lupus activity than women who con-
tinued hydroxychloroquine (Clowse, et. al. 2006).  The 
use of hydroxychloroquine throughout pregnancy in 
patients with lupus minimizes the number of flares and 
hypertensive disorders.  Hydroxychloroquine is safe to 
use during pregnancy, and there have been no “reported 
malformations, growth restriction and ocular, auditory, or 
neurological toxicity in exposed fetus” (Ruiz-Irastorza, 
Khamashta, 2011).  Hydroxychloroquine is secreted in 
breast milk; however, there were no reports of negative 
effects in children who were breastfed.  
In the case of disease reactivation during pregnancy, cor-
ticosteroids are usually used.  Since fluorinated corticoste-
roids diffuse across the placenta, they should not be taken 
during pregnancy.  On the other hand, non-fluorinated 
corticosteroids, (prednisone, prednisolone, methylprednis-
olone, hydrocortisone) are broken down by placental 11 
beta-hydroxysteroid dehydrogenase, and only ten percent 
of drug dosage crosses the placenta.  That said, non-fluo-
rinated corticosteroids are connected to various compli-
cations such as diabetes, preeclampsia, and hypertension; 
therefore, low doses are recommended (prednisone<7.5 
mg/day) (Ruiz-Irastorza, et. al. 2012).  A dose of above ten 
mg/day of prednisone has been linked to a higher chance 
of developing dyslipidemia, arterial hypertension, maternal 
hyperglycemia, and fluid retention.  Non-fluorinated cor-
ticosteroids are only slightly passed into breast milk and 
is permitted during breastfeeding.  However, if the dose is 
high then women should wait four hours after taking the 
corticosteroid to breastfeed.  
Most immunosuppressive medications are stopped during 
pregnancy and breastfeeding, except azathioprine in doses 
up to two and a half mg/kg/day, cyclosporin, and tacrolimus. 
Although cyclosporin has been deemed safe to use during 
pregnancy, it has been linked to an increased chance of pre-
eclampsia, hypertension, and gestational diabetes (Ateka-
Barrutia, Khamashta, 2013).  Mycophenolate mofetil, meth-
otrexate, and cyclophosphamide are not safe to use during 
pregnancy and should be switched to safer drugs.  
NSAIDs are overall safe to use throughout pregnan-
cy if they are limited to short term usage.  However, 
long term use of NSAIDs have been linked to cardiac 
and renal failure, fluid overload, and hypertension in the 
mother, and renal disorders and oligohydramnios in the 
fetus.  The use of these medications should only take 
place at the end of pregnancy, after thirty weeks of ges-
tation (Ostensen, et. al. 2006).  
Antiplatelets and anticoagulants are also used to treat 
lupus.  The use of low-dose aspirin (75-100 mg/day) and 
dipyridamole is safe to use during pregnancy.  Aspirin can 
be used even throughout labor or epidural anesthesia to 
decrease the chance of hemorrhagic issues.  Since hepa-
rins do not diffuse across the placenta, they are safe to 
use throughout pregnancy and breastfeeding.  However, 
warfarin is damaging to the fetus during organogenesis 
(the first six-ten weeks of pregnancy) and therefore 
should not be taken during this timeframe (Ostensen, et. 
al. 2006).  Patients taking these medications should be 
switched to heparin when pregnancy is confirmed.  
Conclusion
Systemic Lupus Erythematosus is a disease with varying 
severity in the population, but one that can have devas-
tating effects on mother and baby. Advances in the under-
standing of the disease as well as treatment and preven-
tion of flare ups have allowed women with lupus to have 
successful and healthy pregnancies with favorable out-
comes. It is imperative however, that women with lupus 
seek guidance from their rheumatologist and obstetrician 
and focus on prenatal care for the best possible outcome 
for mother and baby.
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